Suppr超能文献

[甲基丙二酸血症患儿血浆微小RNA水平的初步研究]

[A preliminary study of plasma microRNA levels in children with methylmalonic acidemia].

作者信息

Li Yan-Fei, Peng Tao, Duan Ran-Ran, Wang Xiao-Han, Gao Hui-Li, Wang Jing-Tao, Teng Jun-Fang, Jia Yan-Jie

机构信息

Department of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2014 Jun;16(6):629-33.

Abstract

OBJECTIVE

To screen out differentially expressed microRNAs (miRNAs) in the plasma of children with methylmalonic acidemia (MMA), to determine the expression of miR-9-1 in plasma and to preliminarily evaluate the significance of miR-9-1 as a biomarker in MMA.

METHODS

Plasma was obtained from 17 MMA children, 10 hyperhomocysteinemia (HHcy) children without MMA (HHcy group), and 10 normal controls. Of 17 MMA children, 12 had HHcy (MMA+HHcy group), and 5 had no HHcy (MMA group). The differentially expressed miRNAs were screened out by miRNA microarray. Differentially expressed miR-9-1 was selected, and plasma miR-9-1 levels were determined by RT-PCR. Urine was collected from MMA patients who received vitamin B12 treatment, and plasma miR-9-1 levels were determined by RT-PCR after treatment.

RESULTS

The miRNA microarray analysis showed that 26 miRNAs were differentially expressed, among which 16 miRNAs (including miR-9-1) were down-regulated over 2 times, while 10 miRNAs were up-regulated over 2 times. The MMA+HHcy , MMA and HHcy groups had significantly down-regulated miR-9-1 compared with the normal control group (P<0.01). The patients who showed a good response to vitamin B12 treatment had significantly increased plasma miR-9-1 levels, without significant difference compared with the normal control group.

CONCLUSIONS

Plasma miR-9-1 is significantly down-regulated in MMA patients, but it is significantly up-regulated after vitamin B12 treatment, suggesting that miR-9-1 may act as a biomarker in monitoring the progression of MMA.

摘要

目的

筛选甲基丙二酸血症(MMA)患儿血浆中差异表达的微小RNA(miRNA),检测miR-9-1在血浆中的表达,并初步评估miR-9-1作为MMA生物标志物的意义。

方法

收集17例MMA患儿、10例无MMA的高同型半胱氨酸血症(HHcy)患儿(HHcy组)及10例正常对照者的血浆。17例MMA患儿中,12例伴有HHcy(MMA+HHcy组),5例无HHcy(MMA组)。采用miRNA芯片筛选差异表达的miRNA。选取差异表达的miR-9-1,通过逆转录聚合酶链反应(RT-PCR)检测血浆miR-9-1水平。收集接受维生素B12治疗的MMA患者的尿液,治疗后通过RT-PCR检测血浆miR-9-1水平。

结果

miRNA芯片分析显示,有26个miRNA差异表达,其中16个miRNA(包括miR-9-1)下调超过2倍,10个miRNA上调超过2倍。与正常对照组相比,MMA+HHcy组、MMA组和HHcy组的miR-9-1均显著下调(P<0.01)。维生素B12治疗反应良好的患者血浆miR-9-1水平显著升高,与正常对照组相比无显著差异。

结论

MMA患者血浆miR-9-1显著下调,但维生素B12治疗后显著上调,提示miR-9-1可能作为监测MMA病情进展的生物标志物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验